GLP-1 Weight Loss Projector

Clinical trial averages show: semaglutide 2.4mg (Wegovy) achieved ~15% body weight loss at 68 weeks in the STEP 1 trial (NEJM, 2021). Tirzepatide 15mg (Zepbound) achieved ~21% at 72 weeks in SURMOUNT-1 (NEJM, 2022). Individual results vary significantly — some participants lost more, some less. These results were achieved alongside reduced-calorie diet and increased physical activity.

Most clinical trial participants began seeing noticeable weight loss within the first 4-8 weeks, with the rate of loss being fastest in the early months and gradually slowing over time. The medications are typically titrated (dose gradually increased) over the first several weeks to reduce side effects, so full effects build over time.

The most common side effects reported in clinical trials include nausea (reported by ~40% of participants), diarrhea, vomiting, constipation, and abdominal pain. These are typically most pronounced during dose escalation and often improve over time. Serious but rare side effects include pancreatitis and gallbladder problems. Always consult your healthcare provider for personalized medical guidance.